#AsOneCorporation

Consolidated sales for March 2026 increased 16.2% year-over-year to exceed 10 billion yen in a single month. All segments recorded significant sales growth: Laboratory +14.6%, Industry +18.1%, Medical +19.3%.

As One Corporation completed the cancellation of 340,000 shares of treasury stock (0.45% of total issued shares) on March 31, 2026. After cancellation, the total number of issued shares stood at 75,012,540 shares.

Consolidated sales for February 2026 increased by 5.1% year-over-year. Laboratory sector grew by 6.4%, Industry by 6.6%, while Medical declined by 2.2%.

AS ONE Corporation resolved to cancel 340,000 shares of common stock (0.45% of total issued shares) as treasury stock on March 31, 2026.

Standalone sales for January 2026 increased 6.8% year-over-year. The Laboratory segment grew by 10.6%, Industry by 4.9%, and Medical declined by 4.1%.

Sales for December 2025 grew year-over-year in all three major sectors, resulting in an overall +9.0% increase year-over-year. The expansion of the EC channel contributed significantly.

For the third quarter of the fiscal year ending March 2026, consolidated net sales were 79.204 billion yen (5.1% increase YoY), operating income was 9.435 billion yen (12.4% increase YoY), and net income attributable to owners of the parent was 6.715 billion yen (12.4% increase YoY).

For the third quarter of the fiscal year ending March 2026, net sales reached 79,204 million yen (Year-over-Year +5.1%), operating income was 9,435 million yen (Year-over-Year +12.4%), and quarterly net income was 6,715 million yen (Year-over-Year +12.4%), all marking record highs.